Janka Hu Plewe G Riddle Mc Et Al. Diabetes Care. 2005 28 2 254-259.

1 Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes A consensus algorithm for the initiation and adjustment of therapy a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 1963-1972. 2 Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004 27 1028-1032. 3 Li Y, Xu W, Liao Z, et al. Induction of long-term...

References

1 Magee MF, Isley WL BARI 2D Trial investigators. Rationale, design, and methods for glycemic cortrol ir the Bypass Argioplasty Revascularizatior Irvestigatior 2 Diabetes BARI 2D Trial. Am J Cardiol 2006 97 20G-30G. 2 Gersteir HC, Riddle MC, Kerdall DM, et al ACCORD Study Group. Glycemia treatmert strategies ir the Actior to Cortrol Cardiovascular Risk ir Diabetes ACCORD trial. Am J Cardiol 2007 99 34i-343i. 3 Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2...

Diabetic neuropathy

Neuropathy Pathophysiology

The term diabetic neuropathy encompasses a wide range of conditions with diverse clinical manifestations see Figures 5.8 and 5.9 . The most common clinical presentation is with chronic sensorimotor DPN and autonomic neuropathy. Although DPN is a diagnosis of exclusion, complex investigations to exclude other conditions are rarely needed. Patients with diabetes should be screened annually for DPN using tests such as pinprick sensation, temperature and vibration perception using a 128 Hz tuning...

Hyperglycemic crisis

It is important to recognize the underlying precipitating factors in the development of severe hyperglycemia, because their treatment may be critical to recovery. The most common precipitating factor in the development of DKA or HHS is infection. Other precipitating factors include cerebrovascular accident, alcohol abuse, pancreatitis, myocardial infarction, trauma, and drugs steroids, antipsychotics, thiazide diuretics, etc. . In addition, new-onset type 1 diabetes or discontinuation of or...

Diabetes in Clinical Practice

Merri Pendergrass Harvard Medical School And and Hypertension Brigham and Women s Hospital Boston Roberta Harrison McDuffie Tulane University Health Science Center Diabetes Program New Orleans Louisiana USA ISBN 978-1-84882-102-6 e-ISBN 978-1-84882-103-3 Springer London Dordrecht Heideberg New York DOI 10.1007 978-1-84882-103-3 A catalogue record for this book is available from the British Library Library of Congress Control Number 2009935337 Springer-Verlag London Limited 2010 Previously...

Noninsulin agents in the management of type diabetes

Eight different classes of medication, in addition to insulin, are currently approved for treatment of hyperglycemia in type 2 diabetes. Beneficial effects of antihyperglycemic agents appear to be mediated predominantly through their ability to lower blood glucose. Studies are currently in progress to determine whether any particular agent or treatment strategy has specific advantages, beyond glucose lowering, in terms of reducing cardiovascular endpoints 1, 2 . Unfortunately, there are few...